Short for Sisonke Heterologous mRNA-1273 boost after prime with Ad26.COV2.S, the SHERPA Study’s primary objective is to evaluate the effectiveness of the heterologous mRNA-1273 (Moderna) boost against COVID-19 infections and severe COVID-19 disease among health care workers.
The study aims to enroll up to 15 000 Sisonke participants who have received either a single or two doses of Ad26.COV2.S. This will allow the study team to investigate the effectiveness of the Moderna COVID-19 vaccine booster against the new variants in South Africa, as well as provide the South African Health Products Regulatory Authority (SAHPRA) with additional data on this vaccine for potential licensing.
Pioneering mRNA technology
Building a healthy nation through research, innovation and transformationRead more
Generating Knowledge - Impacting HealthRead More
Lessen the impact of the HIV epidemic on individuals, families and communitiesRead More